Physician profile
John S Barton
NPI 1942284674
$1,504.66
in general payments reported to CMS, 2019-2025
26 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.64 · 2020: $30.41 · 2021: $172 · 2022: $253 · 2023: $309 · 2024: $210 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.25 | 2021-2025 | Qulipta, Ubrelvy |
| Mylan Specialty L.P. | $214.27 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $103.10 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.19 | 2024-2025 | Caplyta |
| Baudax Bio INC. | $88.84 | 2020-2022 | |
| Lilly USA, LLC | $76.92 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $61.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Olympus Corporation of The Americas | $49.12 | 2025 | Itind System |
| Otsuka America Pharmaceutical, INC. | $47.61 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $46.14 | 2022 | |
| Melinta Therapeutics, LLC | $44.63 | 2019-2025 | Orbactiv, Kimyrsa |
| Daiichi Sankyo INC. | $34.79 | 2023 | Injectafer |
| Abbott Laboratories | $34.61 | 2022 | |
| Axsome Therapeutics, INC. | $31.10 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $29.08 | 2023 | Flumist Quadrivalent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $28.67 | 2019 | |
| Genentech USA, INC. | $28.18 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.00 | 2019 | |
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $26.14 | 2025 | |
| Merck Sharp & Dohme LLC | $23.91 | 2024 | Capvaxive |
| Glaxosmithkline, LLC. | $21.96 | 2023 | Bexsero, Arexvy, Shingrix |
| Viatris Specialty LLC | $20.63 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $18.74 | 2023 | Xarelto |
| Kedrion Biopharma, INC. | $17.02 | 2023 | Kedrab, Koate, Rhogam Ultra-Filtered Plus |
| Phathom Pharmaceuticals, INC. | $14.18 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.